NDA 209176 · Shionogi
Radicava
Edaravone · Intravenous
NovelOrphanDiscontinuedLast checked: Nov 20, 2026Latest source record: Nov 18, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2017
May 5, 2017
Approved uses
1
Original approval plus efficacy supplements
Registered trials
69
18 Phase 3, 6 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
2 products under this application
- RADICAVA · EDARAVONE 60MG/100ML (0.6MG/ML) · SOLUTION, INTRAVENOUS · Discontinued · TE AP
- RADICAVA · EDARAVONE 30MG/100ML (0.3MG/ML) · SOLUTION, INTRAVENOUS · Discontinued · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Edaravone" as an intervention, any sponsor and status, largest first.
- Treatment of Acute Ischemic STroke With Edaravone Dexborneol II (TASTE-2)Pivotal-lookingCompleted
Beijing Tiantan HospitalAcademic, hospital or other
NCT05249920 · 1,362 participants · Start Mar 18, 2022 · Primary completion Feb 17, 2023
Drug: Edaravone Dexborneol Concentrated Solution for injection; Edaravone Dexborneol placebo · For: Acute Ischemic Stroke; Mechanical Thrombectomy; Edaravone Dexborneol and 1 more
Sites: Beijing, China
- Study of Compound Edaravone Injection for Treatment of Acute Ischemic StrokePivotal-lookingCompleted
Jiangsu Simcere Pharmaceutical Co., Ltd.Industry
NCT02430350 · 1,200 participants · Start May 2015 · Primary completion Dec 2016
Drug: Compound Edaravone Injection; Edaravone Injection · For: Acute Ischemic Stroke
Sites: Beijing, China; Fuzhou, China; Guangzhou, China · 48 sites in all
- Safety and Efficacy of Edaravone Dexborneol for Acute Ischemic StrokePivotal-lookingNot yet recruiting
Yi YangAcademic, hospital or other
NCT06645522 · 1,200 participants (planned) · Start Oct 30, 2024 · Primary completion Oct 30, 2026
Drug: Edaravone dexborneol; Placebo · For: Acute Ischemic Stroke
Sites: Changchun, China
- Sublingual Edaravone Dexborneol for Inter-hospital Transfer Acute Ischemic Stroke (SLEDAIS)Pivotal-lookingNot yet recruiting
Xinqiao Hospital of ChongqingAcademic, hospital or other
NCT07682922 · 1,040 participants (planned) · Start Jul 1, 2026 · Primary completion Jul 1, 2028
Drug: Edaravone dexborneol sublingual tablet; Placebo · For: Acute Ischemic Stroke
Sites: Chongqing, China
- Phase III Clinical Trial of Y-2 Sublingual Tablets in the Treatment of Acute Ischemic StrokePivotal-lookingCompleted
Peking University Third HospitalAcademic, hospital or other
NCT04950920 · 914 participants · Start Jun 28, 2021 · Primary completion Aug 10, 2022
Drug: Y-2 sublingual tablets; d-borneol · For: Stroke
Sites: Beijin, China
- The Efficacy and Safety of Edaravone Dexborneol Sequential Therapy in the Treatment of Patients With AISPivotal-lookingStatus unknown
Simcere Pharmaceutical Co., LtdAcademic, hospital or other
NCT06176781 · 880 participants (planned) · Start Dec 28, 2023 · Primary completion Mar 28, 2025
Drug: Edaravone Dexborneol Sequential Therapy; Placebo · For: Subjects With Acute Ischemic Stroke
- Edaravone and Argatroban Stroke Therapy Study for Acute Ischemic StrokePivotal-lookingCompleted
Combination Therapy for Acute Ischemic Stroke Study GroupAcademic, hospital or other
NCT00153946 · 814 participants · Start Aug 2004 · Primary completion Mar 2008
Drug: Edaravone · For: Stroke
Sites: Suita, Japan
- Treatment of Acute Ischemic Stroke With Edaravone Dexborneol Sublingual Tablets in Small Vessel DiseasePivotal-lookingRecruiting
Peking Union Medical College HospitalAcademic, hospital or other
NCT06674460 · 600 participants (planned) · Start Aug 1, 2025 · Primary completion Oct 1, 2027
Drug: Edaravone Dexborneol Sublingual Tablets; Placebo · For: Cerebral Small Vessel Disease; Ischemic Stroke
Sites: Beijing, China
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Radicava (Edaravone)
2024 spending
$4.9M
Beneficiaries
47
383 claims
Per beneficiary
$103,536
$6.20 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $66,883,209 |
| 2021 | $64,882,863 |
| 2022 | $45,010,772 |
| 2023 | $11,072,961 |
| 2024 | $4,866,172 |
Part B: Radicava (Edaravone) · HCPCS J1301
2024 spending
$2.7M
Beneficiaries
33
1,722 claims
Per beneficiary
$81,969
2024 ASP limit $21.90 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $31,056,034 |
| 2021 | $25,067,596 |
| 2022 | $18,578,904 |
| 2023 | $5,984,589 |
| 2024 | $2,704,989 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Edaravone Dexborneol Versus Edaravone Alone for the Treatment of Acute Ischemic Stroke: A Phase III, Randomized, Double-Blind, Comparative Trial.
Xu J, Wang A, Meng X, et al. · Stroke 2021 · Clinical Trial, Phase III, Comparative Study
- Edaravone dexborneol versus placebo on functional outcomes in patients with acute ischaemic stroke undergoing endovascular thrombectomy (TASTE-2): randomised controlled trial.
Wang C, Gu H, Huo X, et al. · BMJ 2026 · Randomized Controlled Trial, Multicenter Study
- Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial.
· Lancet Neurol 2017 · Clinical Trial, Phase III, Randomized Controlled Trial
- Generalizability of Edaravone Efficacy.
Brooks BR, Ennist DL, Beaulieu D, et al. · Muscle Nerve 2026 · Clinical Trial, Phase III, Randomized Controlled Trial
- Safety and Effectiveness of Long-term Intravenous Administration of Edaravone for Treatment of Patients With Amyotrophic Lateral Sclerosis.
Witzel S, Maier A, Steinbach R, et al. · JAMA Neurol 2022 · Multicenter Study, Randomized Controlled Trial
- Edaravone for acute intracerebral haemorrhage.
Yang J, Liu M, Zhou J, et al. · Cochrane Database Syst Rev 2011 · Meta-Analysis, Systematic Review
Sponsor: Shionogi
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.